Findings

What do systematic reviews say?

1,679 questions · 1,720 findings · 335 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 192 · 11.2%GRADE not reported 75 · 4.4%Very low 526 · 30.6%Low 504 · 29.3%Moderate 305 · 17.7%High 118 · 6.9%

Vaginal misoprostol vs surgical evacuation of uterus

Blood loss: post‐treatment haematocrit (%) · early fetal death (less than 24 weeks)

1 finding from 1 review

Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
Low

Vaginal misoprostol vs surgical evacuation of uterus

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · early fetal death (less than 24 weeks)

Vaginal misoprostol may leads to higher pain relief compared with surgical evacuation of uterus (low certainty).

1 finding from 1 review

Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
RR 1.42
1 study · 154 participants
Low

Vaginal misoprostol vs surgical evacuation of uterus

Woman’s satisfaction/acceptability of method · early fetal death (less than 24 weeks)

Vaginal misoprostol showed no clear difference in woman’s satisfaction/acceptability of method compared with surgical evacuation of uterus (low certainty).

1 finding from 1 review

Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
RR 0.67 [0.4, 1.11]
1 study · 45 participants
Low

Vaginal misoprostol vs placebo

Pelvic infection · early fetal death (less than 24 weeks)

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Vaginal misoprostol vs placebo

Nausea · early fetal death (less than 24 weeks)

Vaginal misoprostol showed no clear difference in nausea compared with placebo (low certainty).

1 finding from 1 review

Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
RR 1.38 [0.43, 4.4]
2 studies · 88 participants
Low

Vaginal misoprostol vs placebo

Diarrhoea · early fetal death (less than 24 weeks)

Vaginal misoprostol showed no clear difference in diarrhoea compared with placebo (low certainty).

1 finding from 1 review

Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
RR 2.21 [0.35, 14.06]
2 studies · 88 participants
Low

Vaginal misoprostol vs placebo

Blood loss: haemoglobin difference > 10 g/L · early fetal death (less than 24 weeks)

It is very uncertain whether vaginal misoprostol changes blood loss: haemoglobin difference > 10 g/L compared with placebo (very low certainty).

1 finding from 1 review

Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
RR 1.25 [0.38, 4.12]
1 study · 50 participants
Very low

Vaginal misoprostol vs placebo

Opiate use (as a proxy measure for pain) for all participants on ITT (including those without confirmed AMI) · early fetal death (less than 24 weeks)

It is very uncertain whether vaginal misoprostol changes pain (opiate use) compared with placebo (very low certainty).

1 finding from 1 review

Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
RR 5 [0.25, 101.11]
1 study · 84 participants
Very low

Vaginal misoprostol vs placebo

Woman’s satisfaction/acceptability of method · early fetal death (less than 24 weeks)

Vaginal misoprostol showed no clear difference in woman’s satisfaction/acceptability of method compared with placebo (low certainty).

1 finding from 1 review

Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
RR 1.17 [0.83, 1.64]
1 study · 32 participants
Low

Vaginal misoprostol vs surgical evacuation of uterus

Complete miscarriage · early fetal death (less than 24 weeks)

Vaginal misoprostol may leads to lower complete miscarriage compared with surgical evacuation of uterus (low certainty).

1 finding from 1 review

Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
RR 0.4 [0.32, 0.5]
6 studies · 943 participants
Low

Vaginal misoprostol vs surgical evacuation of uterus

Pelvic infection · early fetal death (less than 24 weeks)

Vaginal misoprostol showed no clear difference in pelvic infection compared with surgical evacuation of uterus (low certainty).

1 finding from 1 review

Medical treatment for early fetal death (less than 24 weeks) 2019 · Cochrane Headline outcomes only
RR 0.73 [0.39, 1.37]
1 study · 618 participants
Low

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Overall survival · women with early breast cancer

Taxane‐containing chemotherapy leads to lower overall survival compared with any chemotherapy without taxane (high certainty).

1 finding from 1 review

Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
HR 0.87 [0.83, 0.92]
27 studies · 39180 participants
High

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Disease‐free progression · women with early breast cancer

Taxane‐containing chemotherapy leads to lower disease‐free progression compared with any chemotherapy without taxane (high certainty).

1 finding from 1 review

Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
HR 0.88 [0.85, 0.92]
29 studies · 41909 participants
High

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Quality of life · women with early breast cancer

1 finding from 1 review

Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 7 participants
Low

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Febrile neutropenia · women with early breast cancer

Taxane‐containing chemotherapy showed no clear difference in febrile neutropenia compared with any chemotherapy without taxane (moderate certainty).

1 finding from 1 review

Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
OR 1.43 [0.89, 2.31]
23 studies · 34154 participants
Moderate

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Neuropathy (including grade 3/4 sensory or motor neuropathy, or both) · women with early breast cancer

Taxane‐containing chemotherapy probably leads to higher neuropathy (including grade 3/4 sensory or motor neuropathy, or both) compared with any chemotherapy without taxane (moderate certainty).

1 finding from 1 review

Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
OR 6.89 [3.23, 14.71]
22 studies · 31033 participants
Moderate

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Cardiotoxicity (including grade 3/4 and congestive cardiac failure) · women with early breast cancer

Taxane‐containing chemotherapy showed no clear difference in cardiotoxicity (including grade 3/4 and congestive cardiac failure) compared with any chemotherapy without taxane (moderate certainty).

1 finding from 1 review

Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
OR 0.87 [0.56, 1.33]
23 studies · 32894 participants
Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Overall survival ( · neoadjuvant therapy for early breast cancer

Taxane followed by anthracyclines showed no clear difference in overall survival ( compared with anthracyclines followed by taxane (moderate certainty).

1 finding from 1 review

Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
HR 0.8 [0.6, 1.08]
2 studies · 947 participants
Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Grade 3 to 4 neutropenia · adjuvant therapy for early breast cancer

Taxane followed by anthracyclines leads to lower adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (high certainty).

1 finding from 1 review

Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
RR 0.62 [0.4, 0.97]
4 studies · 279 participants
High

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Adverse events: neurotoxicity (grade 3/4) ( · adjuvant therapy for early breast cancer

Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).

1 finding from 1 review

Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
RR 0.78 [0.25, 2.46]
3 studies · 162 participants
Low